Pharmacokinetic analysis have largely taken place in live rodents as well as rodent and human microsomes.
Owing to the heterogeneity of analysis and paucity of human experiments conducted thus far, the pharmacokinetic profile of mitragynine is not complete.
However, initial pharmacokinetic studies in humans have yielded preliminary information.
In a study of 10 healthy volunteers taking orally administered mitragynine from whole leaf preparations, mitragynine appeared to have a much longer half-life than typical opioid agonists (7–39 hours) and reached peak plasma concentration within 1 hour of administration.
Pharmacokinetic analysis have largely taken place in live rodents as well as rodent and human microsomes. Owing to the heterogeneity of analysis and paucity of human experiments conducted thus far, the pharmacokinetic profile of mitragynine is not complete. However, initial pharmacokinetic studies in humans have yielded preliminary information. In a study of 10 healthy volunteers taking orally administered mitragynine from whole leaf preparations, mitragynine appeared to have a much longer half-life than typical opioid agonists (7–39 hours) and reached peak plasma concentration within 1 hour of administration.
Mitragynine